Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for Heron Therapeutics (HRTX) over the last 10 years, with Q3 2025 value amounting to $12.9 million.

  • Heron Therapeutics' Cost of Revenue rose 1795.48% to $12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.9 million, marking a year-over-year decrease of 97.4%. This contributed to the annual value of $47.1 million for FY2024, which is 3039.19% down from last year.
  • Heron Therapeutics' Cost of Revenue amounted to $12.9 million in Q3 2025, which was up 1795.48% from $11.6 million recorded in Q2 2025.
  • Heron Therapeutics' Cost of Revenue's 5-year high stood at $25.2 million during Q3 2021, with a 5-year trough of $11.0 million in Q3 2024.
  • For the 5-year period, Heron Therapeutics' Cost of Revenue averaged around $17.2 million, with its median value being $17.8 million (2022).
  • In the last 5 years, Heron Therapeutics' Cost of Revenue skyrocketed by 10140.63% in 2021 and then plummeted by 4591.09% in 2024.
  • Heron Therapeutics' Cost of Revenue (Quarter) stood at $24.5 million in 2021, then decreased by 27.41% to $17.8 million in 2022, then plummeted by 30.64% to $12.3 million in 2023, then decreased by 10.31% to $11.1 million in 2024, then grew by 17.05% to $12.9 million in 2025.
  • Its last three reported values are $12.9 million in Q3 2025, $11.6 million for Q2 2025, and $12.3 million during Q1 2025.